Company intelligence / Profile preview
T-MAXIMUM Biopharmaceuticals
Suzhou, Jiangsu, Chinalinkedin.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
T-MAXIMUM’s lead program, MT027, is an allogeneic universal CAR-T targeting B7-H3 in recurrent high-grade glioma and other solid tumors. Early clinical data show breakthrough efficacy and manageable safety. The company has received Orphan Drug Designation from the U.S. FDA for MT027, with Phase 1 trials ongoing or imminent in the U.S. Additional candidates include MT026 targeting IL13Rα2 for solid tumors and MT020 for B-cell autoimmune diseases, both showing promising preclinical or early clinical results.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- CAR-T cell therapyAllogeneic CAR-T cell therapyGene therapy (CRISPR-based)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
WuXi Advanced Therapies/WuXi ATU – strategic partnership on CTDMO services including manufacturing, IND filing, process development for UCAR‑T product MT‑027GenScript Biotech – strategic alliance on cGMP sgRNA production to support gene-editing therapies
Beyond the preview
Go deeper on T-MAXIMUM Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-MAXIMUM Biopharmaceuticals.